Login / Signup

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.

Beatriz GrosHannah RossMaureen NwabuezeNathan Constantine-CookeLauranne A A P DerikxMathew LyonsClaire O'HareColin NobleIan D ArnottGareth-Rhys JonesCharlie W LeesNikolas Plevris
Published in: Therapeutic advances in gastroenterology (2024)
VDZ effectiveness appears enduring with favourable long-term safety profile. VDZ persistence was influenced by previous exposure to biologics/small molecules, disease distribution and steroid use at baseline in our study.
Keyphrases
  • ulcerative colitis
  • randomized controlled trial
  • systematic review